Pregnant women with red cell antibodies, who are assessed as being at high risk of requiring a blood transfusion, should have a cross-match sample taken at least every week.

Current BCSH guidelines require a sample no more than 72 hours old for providing compatible blood in
pregnancy,but do allow a deviation to the 3-day rule for individual cases such as high-risk women with placenta praevia without red cell antibodies where weekly samples can be taken, as long as a risk assessment is made and recorded in each individual case

In high-risk women with red cell antibodies where a sample every 72 hours is not feasible, a sample should be taken once a week and if transfusion is required a new sample should be taken immediately, to exclude new antibody development. However, in the event of life threatening haemorrhage, urgent transfusion should not be delayed and close liaison with the hospital transfusion laboratory is vital.

Treatment with therapeutic doses of subcutaneous LMWH should be employed during the remainder of the pregnancy and for at least 6 weeks postnatally and until at least 3 months of treatment has been given in total.

• LMWH should not be given for 4 hours after use of spinal anaesthesia or after the epidural catheter has been removed
• and the catheter should not be removed within 12 hours of the most recent injection.

The Green Top Guidleine 37 a  ( VTE Prevention in Pregnancy and Puerperium) has very useful charts for VTE risk assessment-  these can be downloaded HERE

Read about Intrapartum Care in VBAC-

https://obgresource.com/2021/12/10/intrapartum-care-in-vbac-2/

Women can be reassured that long-term survival after breast cancer is not adversely
affected by pregnancy.

According to Guidance from the British Committee
for Standards in Haematology, it is greater than 2 gram/dL

Aspirin is not recommended for thromboprophylaxis in obstetric patients.